"With the progress we are making both in the clinical programmes and in discovery, we expect another exciting year,"
e-Therapeutics () remains upbeat on its new discovery platform that it said is achieving productivity rates well above the norm.
Molecule selection and testing across seven projects had suggested more than 25% of screened compounds were both active and more potent than any previously reported.
“For example, initial results from our most recent project, which sought potent small molecule inhibitors of TNFα, a major inflammatory cytokine, produced a yield rate of potent molecules above 40%, even after initial toxicity screening,” said acting chairman and chief executive Malcolm Young.
These yield rates are much higher than published rates for conventional drug discovery, he added.
Cytokines are small cells that affect the behaviour of other cells.
In its clinical programmes, e-therapeutics recently dosed its first patient for a Phase 1b trial in pancreatic and hepatocellular cancers.
The final patient has also been enrolled in a US study into brain cancer. This cohort is being dosed at 36 mg/kg with one of the group presently on their seventh cycle at this dose level.
“Unlike the UK trial, there have been no dose-limiting toxicities determined at the current dosage, although the patients have experienced similar short-term side effects to those observed in the UK,” Young said.
"With the progress we are making both in the clinical programmes and in discovery, we expect another exciting year, he concluded.
Shares rose 3% to 41p.
NO INVESTMENT ADVICE
The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...
In exchange for publishing services rendered by the Company on behalf of e-Therapeutics plc named herein, including the promotion by the Company of e-Therapeutics plc in any Content on the Site, the Company receives...
FOR OUR FULL DISCLAIMER CLICK HERE